The US FDA has approved Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for generic Atacand HCT tablets to treat hypertension. Candesartan Cilexetil and Hydrochlorothiazide Tablets in 16/12.5mg, 32/12.5mg and 32/25mg ...
Tags: US FDA, hypertension medication, ANDA, hypertension
Inhaled nitric oxide drug products developer GeNO has received four additional US patents on its proprietary inhaled nitric oxide (NO) generation chemistry and delivery technology, bringing the total number of US patents to sixteen. The ...
Tags: inhaled nitric oxide drug, NO, NO2, GeNO
Fujifilm Medical Systems USA has received an ONC-ATCB 2011/2012 certification for Synapse MU 3.0. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under ...
Tags: Fujifilm Medical Systems, ONC-ATCB 2011/2012 certification
Daiichi Sankyo has gained FDA approval to package product at its packaging facility located in Bethlehem, Pennsylvania, US. The Pennsylvania facility will package some of the company's products for cardiovascular and metabolic ...
Tags: FDA, medical product, expansion, business operations
Pharmaceutical company in the US, Merck Sharp and Dohme (MSD) has opened a new $21m packaging facility in Pandaan, Pasuruan, Indonesia, in an effort to step up its production for the Indonesian and Asian markets. The plant, which was ...
Tags: Medicine Packaging, Pharmaceutical, packaging facility
Daiichi Sankyo Mexico, a subsidiary of Daiichi Sankyo Company, has introduced antihypertensive franchise olmesartan medoxomil in Mexico under the name, Openvas. The company has also unveiled Openvas Co, a combination preparation for use ...
Tags: antihypertensive franchise olmesartan medoxomil, pharmaceuticals
Theravance has entered into a research partnership with Merck, known as MSD outside the US and Canada, for the development of potential cardiovascular therapeutics to treat hypertension and heart failure. As per the agreement, Merck will ...
Tags: Cardiovascular Therapeutics, Theravance, Merck, MSD
The European Commission has cleared an oral anticoagulant, Eliquis, developed by Bristol-Myers Squibb (BMS) and Pfizer. Eliquis 5mg, trade name of apixaban in Europe, is indicated as a twice-daily drug for preventing strokes and systemic ...
Tags: BMS-Pfizer Oral Anticoagulant, oral anticoagulant, Eliquis, apixaban
Wockhardt has received final approval from the US Food and Drug Administration ((FDA) to market extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used to treat hypertension. Felodipine is the generic name for ...
Teva UK, a part of Teva Pharmaceutical Industries, has announced the launch of generic Irbesartan tablets. Irbesartan, a generic version of Aprovel (Irbesartan) by Sanofi Pharma Bristol-Myers Squibb SNC, is indicated to treat essential ...
Tags: Irbesartan Tablets, antihypertensive medicinal product regimen
The US Food and Drug Administration(FDA)has granted 510(k)clearance to AtCor Medical's new blood pressure cuff-based system,designed for measuring brachial and central aortic blood pressure simultaneously. Available in ...
The US Food and Drug Administration(FDA)approved Actelion Pharmaceuticals'supplemental new drug application(sNDA)for second generation Veletri(epoprostenol)for injection. Veletri(epoprostenol)for injection is indicated for the treatment ...
Tags: FDA, Actelion sNDA, Actelion Pharmaceuticals, Veletri
The South East Health Technologies Alliance (SEHTA) has launched a UK Healthcare Innovation Hub, which will act as a meeting point for entrepreneurs, academics, researchers and policymakers to develop new and innovative healthcare concepts. ...
Tags: Healthcare Innovation, eco-independent living, elderly people
GeNO has received two new US patents for its proprietary nitric oxide(NO)generation and delivery technology. The US patent no.8,173,072 describes the conversion of nitrogen dioxide(NO2)to nitric oxide(NO),using the GeNO cartridge ...
Tags: nitric oxide(NO)generation, nitric oxide(NO)delivery, US Patents, GeNO
The US Food and Drug Administration (FDA) has accepted GeNO's filing of new drug application (NDA) for GeNOsyl MVG-2000 nitric oxide delivery system. GeNOsyl nitric oxide is a vasodilator which is indicated for the treatment of term and ...
Tags: GeNOsyl nitric oxide, FDA